Emerging Leaders Workshop at BIO

Readers are well aware of the benefits of attending the annual International BIO Convention--personally, it's an event where I can count on getting feedback about our publications from a range of senior executives who drive the action we write about in drug development.

This year, we're thrilled to partner with BIO to highlight a workshop targeting another strong reader segment of ours: mid-level product planners and managers.

New product commercialization is a critical skill. As BIO notes, there has been a systematic decline in the ability of new products to replace those going off patent. Competition is aggressive, and new regulatory pressures require future drug development leaders to possess a dynamic mix of logistical and strategic knowledge. And there's no better place to get that this year than at the Emerging Leaders Workshop, taking place during the 2011 International BIO Convention (held in Washington, DC, June 27-30).

For those with two to five years experience, this $449 one-and-a-half day workshop (which includes access to the BIO Exhibition) is a compelling opportunity to learn from the best and network with similarly situated peers. Confirmed speakers include Joshua Boger (Founder, Vertex Pharmaceuticals) and Kathleen Weldon Tregoning (VP Government Strategy, Biogen Idec).

Click here to view the full agenda, with details on each strategic learning session and commercial simulations. Act now as we're limiting space to just 100 emerging leaders.

I'll also be at the Emerging Leaders Meet-up (June 27, 7:15 pm at the Newseum during the BIO Welcome Reception) and encourage you to take advantage of the networking opportunities as well. - Arsalan Arif (twitter | email)

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.